Noven Pharmaceuticals Inc. (NOVN) Provides Update on Lidoderm® Patent Challenge
7/2/2012 11:11:22 AM
MIAMI & NEW YORK--(BUSINESS WIRE)--Noven Pharmaceuticals, Inc. today provided an update on the status of its pending Abbreviated New Drug Application (ANDA) seeking approval to market a lidocaine topical patch 5%. Noven’s lidocaine topical patch 5% is a generic version of Endo Pharmaceuticals’ Lidoderm®. As previously announced, on May 15, 2012, Noven notified Endo and its partners (Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA) under the Hatch-Waxman Act that Noven’s ANDA had been accepted for review by the FDA and that it included a paragraph IV certification.